MXCT shows concerning financial deterioration with revenue declining 14.5% to $33.0M while operating cash flow losses worsened 24.6% to -$34.4M, though the company achieved significant milestone revenue growth and launched a new DTx platform.
The substantial decline in financial performance coupled with reduced clinical programs (from 18 to 13) and lower milestone opportunities (from $220M to $130M) suggests weakening business momentum. However, the tripling of milestone revenue received (from $10M to over $30M) and successful SeQure integration provide some positive counterbalances to the deteriorating operational metrics.
MXCT experienced broad-based financial decline with revenue falling 14.5% and gross profit dropping 15% year-over-year, while operating cash flow losses deepened significantly to -$34.4M. The balance sheet contracted meaningfully with current assets down 31.1%, cash declining 28%, and total assets shrinking 15.4%, indicating substantial cash consumption. The overall financial picture signals a company burning through resources faster while generating less revenue, though the reduced interest expense and maintained equity base suggest adequate liquidity for near-term operations.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Current assets declined 31.1% — monitor working capital adequacy and short-term liquidity.
Cash decreased 28% — monitor burn rate and upcoming capital needs.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Equity decreased 16.9% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 15.4% — asset sales, write-downs, or balance sheet optimization underway.
Inventory reduced 15.3% — lean inventory management or demand outpacing supply.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue softened 14.5% — monitor whether this is cyclical or structural.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →